Comprehensive medication guide to Qbrexza including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
Commercially insured patients using an in-network pharmacy under the Journey Total Access Program can pay as little as $0 if their plan covers Qbrexza, or no more than $50 if it does not. Medicare does not commonly cover Qbrexza.
Estimated Cash Pricing
Approximately $840–$939 retail for a 30-cloth (30-day) supply; as low as $630 with GoodRx or $653 with SingleCare coupons at participating pharmacies. No generic version is available.
Medfinder Findability Score
72/100
Summarize with AI
On this page
Qbrexza (glycopyrronium cloth, 2.4%) is a prescription topical anticholinergic medication used to treat primary axillary hyperhidrosis — excessive underarm sweating — in adults and pediatric patients 9 years of age and older. It was the first FDA-approved topical product specifically indicated for this condition, approved in June 2018.
Qbrexza comes as single-use, pre-moistened cloths packaged in individual pouches. Each cloth is applied once daily to both underarms using a single wipe. It is manufactured and distributed by Journey Medical Corporation (originally developed by Dermira, Inc.). As of 2026, there is no FDA-approved generic version of Qbrexza.
Primary axillary hyperhidrosis affects an estimated 10 million people in the United States. Qbrexza is not a controlled substance and can be prescribed by any licensed prescriber, including dermatologists, primary care physicians, nurse practitioners, and telehealth providers.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Qbrexza works by blocking muscarinic acetylcholine receptors on sweat glands in the underarm. Acetylcholine is a neurotransmitter that the nervous system uses to signal sweat glands to produce sweat. When glycopyrronium — the active ingredient in Qbrexza — occupies these receptors, acetylcholine cannot bind to them, and the signal to sweat is blocked.
Unlike antiperspirants, which form a temporary plug at the top of the sweat duct after sweat is already produced, Qbrexza reduces the amount of sweat the body makes in the first place. This targeted, at-the-source approach is why Qbrexza can be more effective than antiperspirants for patients with moderate to severe primary axillary hyperhidrosis.
Because glycopyrronium receptors exist throughout the body — not just in the underarms — some systemic absorption from the skin can cause anticholinergic side effects in other areas. These include dry mouth, blurred vision, urinary hesitancy, and constipation. The topical route limits systemic absorption compared to oral anticholinergics, but does not eliminate it entirely.
2.4% — Pre-moistened cloth (single-use)
One cloth applied to both underarms once daily. Each cloth contains 105 mg glycopyrronium tosylate (equivalent to 66 mg glycopyrronium). Available in 30-cloth boxes (30-day supply) and 12-cloth boxes.
As of 2026, Qbrexza is not listed on the FDA's drug shortage database — meaning there is no national manufacturing shortage. However, many patients still have difficulty finding it at their local pharmacy. Qbrexza is brand-name only (no generic available), expensive (approximately $840–$939 cash per 30-day supply), and not stocked at every retail location. The manufacturer's in-network pharmacy program routes most fills through a limited set of participating pharmacies, further complicating access.
Most community pharmacies can special-order Qbrexza within 1–3 business days even if they don't keep it on hand. In-network pharmacies in the Journey Total Access Program are more likely to stock it regularly and offer home delivery. Commercially insured patients can reduce their cost to $0–$50 through this program.
If you're struggling to locate Qbrexza, medfinder calls pharmacies near you to check availability and texts you the results — saving you the time and frustration of calling pharmacies yourself.
Qbrexza is not a controlled substance and does not require any DEA scheduling exemption to prescribe. Any licensed healthcare provider with prescribing authority can write a Qbrexza prescription. However, because many insurance plans require prior authorization, providers experienced with hyperhidrosis documentation are best positioned to support access.
Telehealth is a convenient option for patients in rural areas or those with limited access to dermatology. The official Qbrexza website (getqbrexza.com) connects patients with the Populus telehealth platform, where a licensed provider can evaluate the patient and send a prescription to their preferred pharmacy. Many general telehealth platforms also have the ability to prescribe Qbrexza depending on state regulations.
No. Qbrexza (glycopyrronium cloth, 2.4%) is not a controlled substance and is not scheduled by the DEA. It does not require any special DEA registration to prescribe, and there are no federal restrictions on the number of refills. Any licensed prescriber with prescribing authority can write a Qbrexza prescription, including dermatologists, primary care physicians, nurse practitioners, physician assistants, and telehealth providers.
While Qbrexza does not have controlled substance restrictions, it does require a valid prescription from a licensed healthcare provider. It cannot be purchased over the counter. Insurance plans may impose their own coverage requirements such as prior authorization or step therapy, but these are payer-level rules, not DEA scheduling requirements.
The most frequently reported side effects of Qbrexza (occurring in ≥2% of clinical trial subjects) include:
Know what you need? Skip the search.
Sofdra (sofpironium topical gel, 12.45%)
FDA-approved topical anticholinergic gel for primary axillary hyperhidrosis in patients 9+. Applied once daily like a deodorant. Similar mechanism to Qbrexza; some patients report more tolerable side effect profile.
Botox (onabotulinumtoxinA) injections
FDA-approved for severe primary axillary hyperhidrosis when topical therapy is inadequate. In-office injections every 4–6 months. No daily medication required. Covered by many commercial plans with prior authorization.
Drysol (aluminum chloride hexahydrate 20%)
Prescription-strength antiperspirant applied nightly. First-line therapy for mild to moderate hyperhidrosis. Works differently from Qbrexza (plugs sweat ducts rather than blocking receptors). Inexpensive with broad insurance coverage.
Oral glycopyrrolate or oxybutynin
Off-label oral anticholinergics used for systemic hyperhidrosis management. Generic versions cost $15–$30/month. Higher systemic side effect burden than topical Qbrexza. Not FDA-approved for hyperhidrosis specifically.
Prefer Qbrexza? We can find it.
Other anticholinergic medications (atropine, benztropine, darifenacin, scopolamine)
majorCoadministration may result in additive anticholinergic adverse effects including severe dry mouth, urinary retention, constipation, and blurred vision. Avoid coadministration.
Antihistamines (diphenhydramine/Benadryl, hydroxyzine, brompheniramine, carbinoxamine)
moderateFirst-generation antihistamines have significant anticholinergic activity. Concurrent use with Qbrexza may increase anticholinergic side effect burden. Monitor closely.
Overactive bladder medications (oxybutynin, tolterodine, solifenacin, trospium)
majorThese anticholinergic bladder medications may cause additive urinary retention and anticholinergic effects when used with Qbrexza. Avoid coadministration.
Tricyclic antidepressants (amitriptyline, desipramine, nortriptyline, amoxapine)
moderateTCAs have significant anticholinergic burden. Concurrent use may increase dry mouth, constipation, blurred vision, and urinary hesitancy. Use with caution and monitor closely.
Parkinson's disease medications (benztropine, trihexyphenidyl)
majorThese anticholinergic drugs used for Parkinson's disease or drug-induced movement disorders should not be used concurrently with Qbrexza.
Qbrexza (glycopyrronium cloth, 2.4%) represents a meaningful treatment advance for the millions of Americans dealing with primary axillary hyperhidrosis. As the first FDA-approved topical cloth for this condition, it provides a targeted, at-home daily option that reduces sweating at the source — without the need for in-office procedures or systemic oral medications.
The main challenges with Qbrexza are cost and access. As a brand-name-only medication, the retail price ($840–$939/month) can be prohibitive without insurance or savings programs. The Journey Total Access Program can dramatically reduce cost for commercially insured patients, but Medicare patients and those without commercial insurance face steeper barriers.
If you've been prescribed Qbrexza and are struggling to find it at a pharmacy near you, medfinder calls pharmacies on your behalf to locate which ones have it in stock — texting you the results so you don't have to make the calls yourself. medfinder covers all medications and is here to help patients navigate the prescription process from prescription to pharmacy.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini